Axonics Modulation Technologies Inc (NASDAQ: AXNX), developer of the rechargeable Sacral Neuromodulation (r-SNM) system urinary and bowel dysfunction treatment, declared on Wednesday that it has received Health Canada approval (Homologation d'un instrument medical) to market its External Trial System, an additional element of the Axonics r-SNM system.
The company added that it had previously received Health Canada approval for its miniaturised rechargeable implantable neurostimulator, tined lead, patient and clinician programmers, charger and related accessories. The External Trial System is used to help identify responders to Sacral Neuromodulation therapy prior to a permanent implant. It is composed of a temporary, single-use disposable external stimulator that is connected to either a Tined Lead or a temporary Peripheral Nerve Evaluation (PNE) Lead, depending on the preferred trial method.
Currently, Axonics is conducting a 129-patient pivotal clinical study for urinary incontinence patients under a US FDA Investigational Device Exemption. The enrolment and implant phase was completed in late June 2018 and the company said it expects to file a pre-market approval (PMA) application for FDA approval in the US after the six-month post-implant endpoint has been reached.
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection